Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing innovative anti-infective therapies, notably ORLYNVAH®, the first FDA-approved oral penem antibiotic for uncomplicated urinary tract infections in women. Its core business involves advancing sulopenem, a potent antibiotic targeting resistant gram-negative bacteria, through clinical development, regulatory approval, and potential commercialization in the U.S. and globally, addressing critical needs in resistant infections and antimicrobial resistance.
This description was generated via AI from an annual report. Updated about 1 year ago.